Bruker (BRKR) Stock Overview
Develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
BRKR Community Fair Values
Create NarrativeSee what 30 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Bruker Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$35.34 |
| 52 Week High | US$56.22 |
| 52 Week Low | US$28.53 |
| Beta | 1.19 |
| 1 Month Change | -11.14% |
| 3 Month Change | -26.39% |
| 1 Year Change | -18.67% |
| 3 Year Change | -54.52% |
| 5 Year Change | -45.56% |
| Change since IPO | 53.24% |
Recent News & Updates
Recent updates
Analysts Have Been Trimming Their Bruker Corporation (NASDAQ:BRKR) Price Target After Its Latest Report
Feb 15
Bruker: Attractive Valuation Ahead Of An Earnings Inflection
Jan 09Bruker Corporation's (NASDAQ:BRKR) Shares Bounce 26% But Its Business Still Trails The Industry
Nov 26Why Investors Shouldn't Be Surprised By Bruker Corporation's (NASDAQ:BRKR) 31% Share Price Plunge
Aug 10Revenues Working Against Bruker Corporation's (NASDAQ:BRKR) Share Price
Jun 25A Look At The Fair Value Of Bruker Corporation (NASDAQ:BRKR)
May 31Bruker's (NASDAQ:BRKR) Soft Earnings Don't Show The Whole Picture
May 16Does Bruker (NASDAQ:BRKR) Have A Healthy Balance Sheet?
Apr 26Bruker Corporation: An Investor Could Do Worse
Apr 07Should You Think About Buying Bruker Corporation (NASDAQ:BRKR) Now?
Apr 04Shareholder Returns
| BRKR | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 5.1% | 1.4% | -1.6% |
| 1Y | -18.7% | -6.7% | 15.2% |
Return vs Industry: BRKR underperformed the US Life Sciences industry which returned -7% over the past year.
Return vs Market: BRKR underperformed the US Market which returned 15.9% over the past year.
Price Volatility
| BRKR volatility | |
|---|---|
| BRKR Average Weekly Movement | 6.8% |
| Life Sciences Industry Average Movement | 8.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: BRKR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BRKR's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1960 | 11,085 | Frank Laukien | www.bruker.com |
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions.
Bruker Corporation Fundamentals Summary
| BRKR fundamental statistics | |
|---|---|
| Market cap | US$5.45b |
| Earnings (TTM) | -US$22.50m |
| Revenue (TTM) | US$3.44b |
Is BRKR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BRKR income statement (TTM) | |
|---|---|
| Revenue | US$3.44b |
| Cost of Revenue | US$1.79b |
| Gross Profit | US$1.65b |
| Other Expenses | US$1.67b |
| Earnings | -US$22.50m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 47.95% |
| Net Profit Margin | -0.65% |
| Debt/Equity Ratio | 73.7% |
How did BRKR perform over the long term?
See historical performance and comparisonDividends
Does BRKR pay a reliable dividends?
See BRKR dividend history and benchmarks| Bruker dividend dates | |
|---|---|
| Ex Dividend Date | Mar 23 2026 |
| Dividend Pay Date | Apr 07 2026 |
| Days until Ex dividend | 4 days |
| Days until Dividend pay date | 11 days |
Does BRKR pay a reliable dividends?
See BRKR dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/26 05:41 |
| End of Day Share Price | 2026/03/26 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bruker Corporation is covered by 28 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |